Welcome to our dedicated page for Ardelyx SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech filing packed with pharmacology data can feel like decoding another language, and Ardelyx’s reports are no exception. Each Ardelyx annual report 10-K simplified on Stock Titan lays out pivotal details—cash runway, Phase 3 results for tenapanor, and royalty streams from overseas partners—that investors must grasp before the next catalyst hits. Our platform turns those dense pages into plain-English answers, giving you Ardelyx SEC filings explained simply without hours of scrolling.
Need specific numbers fast? Open any Ardelyx quarterly earnings report 10-Q filing and our AI instantly flags enrollment costs, FDA meeting minutes, and revenue from IBS-C sales. Toggle to Ardelyx insider trading Form 4 transactions or set alerts for Ardelyx Form 4 insider transactions real-time to spot executive stock moves before markets react. Curious about sudden news? The moment management files an Ardelyx 8-K material events explained notice—whether a trial read-out or partnership amendment—you’ll see a concise summary plus contextual ratios that matter.
Researchers, portfolio managers, and retail traders rely on different forms for different insights. The proxy statement section answers questions like “Ardelyx proxy statement executive compensation” by detailing option grants and pay mixes. “Understanding Ardelyx SEC documents with AI” also means seeing drug milestone obligations right beside balance-sheet impacts. From tracking Ardelyx executive stock transactions Form 4 to diving into an Ardelyx earnings report filing analysis, every disclosure updates in real time, complete with expert commentary so you can act on data instead of digging for it.
Michael G. Raab, President & CEO and Director of Ardelyx, Inc. (ARDX), reported a sale of 45,687 shares of common stock on 08/21/2025 at a price of $5.9317 per share. The filing states the sale was an automatic sell-to-cover to satisfy tax withholding upon vesting of restricted stock units. After the transaction, Mr. Raab beneficially owns 1,502,250 shares directly, plus 24,364 shares held in his living trust and 1,000 shares held in trusts for his children. No derivative transactions are reported in this Form 4. The form is signed by an attorney-in-fact and dated 08/25/2025.
Elizabeth A. Grammer, Chief Legal and Administrative Officer of Ardelyx, Inc. (ARDX), reported the disposition of 5,841 shares of the issuer's common stock on 08/21/2025. The sale was executed at $5.9317 per share under code S(1) and is described as an automatic sell-to-cover tied to the vesting of restricted stock units to satisfy withholding taxes. Following the transaction, Ms. Grammer beneficially owned 305,890 shares, held directly. The form is signed by the reporting person on 08/25/2025.
Eric Duane Foster, Chief Commercial Officer of Ardelyx, Inc. (ARDX), reported a routine stock transaction dated 08/21/2025. Pursuant to an automatic sell-to-cover tied to the vesting of restricted stock units, 15,308 shares of Common Stock were sold at an average price of $5.9317 per share to satisfy applicable tax withholding. After the sale, Mr. Foster beneficially owned 301,498 shares. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Foster on 08/25/2025. No derivatives or other transactions are reported.
Ardelyx, Inc. is reported to have a significant institutional stake held by Janus Henderson Group plc. The filing shows Janus Henderson beneficially owns 15,057,940 shares, representing 6.3% of the outstanding common stock, with shared voting and shared dispositive power over 15,057,940 shares. A related subsidiary, JHIUS, is disclosed as potentially beneficial owner of 14,928,999 shares (6.2%) and, together with JHIUKL and JHIAIFML, is identified as an indirect subsidiary that serves as a registered investment adviser to Managed Portfolios. The filer certifies these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Ardelyx (ARDX) Q2-25 10-Q highlights
Total revenue rose 33% YoY to $97.7 m, driven by 84% growth in IBSRELA sales to $65.0 m. XPHOZAH sales fell 33% to $25.0 m after Medicare moved the drug into the ESRD PPS bundle on 1 Jan 25. Six-month revenue reached $171.8 m (+44%).
Gross margin remained high; cost of goods sold was $12.4 m (12.7% of revenue). Operating expenses climbed 29% to $99.7 m as SG&A spending supporting commercial expansion hit $84.0 m; R&D was $15.7 m. Net loss widened to $19.1 m (-$0.08/sh) versus -$16.5 m (-$0.07/sh) a year earlier; six-month loss totalled $60.2 m.
Balance sheet: cash, equivalents and short-term investments stand at $238.5 m. On 30 Jun 25 Ardelyx drew a new $50 m Term E loan, lifting total debt to $201.4 m; another $100 m is available through 2026. Interest-only payments run to Jul-28, but the blended rate on existing tranches is SOFR + 4–8% plus fees.
Other items: a $5 m milestone from Fosun (China NDA approval) booked in Q1. Non-cash royalty revenue from Kyowa Kirin (Japan) was $1.4 m. The $75 m AstraZeneca termination royalty is now fully amortized. Litigation over CMS bundling of XPHOZAH continues; oral arguments are scheduled for Sep-25.
Liquidity runway is solid, but profitability depends on sustaining IBSRELA momentum and offsetting XPHOZAH reimbursement headwinds.
Ardelyx, Inc. (ARDX) has amended its February 2022 Loan & Security Agreement for the fifth time, securing an immediate $50 million senior secured term loan ("Term E") and gaining access to an additional $100 million of committed capital in two optional $50 million tranches ("Term F" and "Term G").
Key economics include: (1) Term E pricing at 4.00% plus 0.022% plus 1-month SOFR, with a SOFR floor of 4.70%; (2) optional Term F/G pricing at SOFR + 4.95%, floored at 3.50%; (3) interest-only payments until maturity—July 1, 2028 for Term E and July 1, 2030 for Term F/G. The company paid a $250k draw fee for Term E and a $1.0 million facility fee for the incremental loans.
The facility remains collateralized and carries back-end fees of 4.95% (Term E) and 3.45% (Term F/G) of principal, payable upon maturity, acceleration, or prepayment. No changes were disclosed to covenants or security packages.
Investment view: The amendment immediately bolsters liquidity and provides flexible growth or runway capital through 2026, but materially increases secured debt capacity and locks in high floating-rate interest costs. Investors should weigh the near-term cash benefit against potential future leverage and interest-expense drag.
Millennium Management LLC, along with affiliated entities, has reported acquiring a significant stake in Ardelyx. According to the Schedule 13G filing dated June 28, 2025, the reporting persons collectively own 12,099,947 shares, representing a 5.1% ownership in the company.
The reporting persons include:
- Millennium Management LLC (Delaware)
- Millennium Group Management LLC (Delaware)
- Israel A. Englander (United States)
All three parties share voting and dispositive power over the reported shares, with no sole voting or dispositive power. The securities were not acquired for the purpose of changing or influencing control of Ardelyx. The shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Mr. Englander.
FAQ
What is the current stock price of Ardelyx (ARDX)?
What is the market cap of Ardelyx (ARDX)?
